adenine has been researched along with Dyslipidemias in 18 studies
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 9.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| " Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date." | 7.75 | Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. ( Cope, D; Iskander, E; Mikhail, N, 2009) |
| " Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals." | 6.75 | Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 5.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| " Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date." | 3.75 | Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. ( Cope, D; Iskander, E; Mikhail, N, 2009) |
| " nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients." | 2.76 | Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). ( Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011) |
| " Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals." | 2.75 | Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010) |
| "The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy." | 2.44 | [Tenofovir as a strategy to avoid or limit adverse effects]. ( Portilla, J, 2008) |
| "Dyslipidemia is associated with aggressive periodontitis, a condition characterized by the rapid destruction of the periodontium." | 1.42 | Associations of apolipoprotein E and low-density lipoprotein receptor-related protein 5 polymorphisms with dyslipidemia and generalized aggressive periodontitis in a Chinese population. ( Chen, Z; Feng, X; Gao, H; Hou, J; Lu, R; Meng, H; Shi, D; Tian, Y; Wang, X; Xu, L; Zhang, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, HY | 1 |
| Tseng, TC | 1 |
| Hwang, EG | 1 |
| Jung, EA | 1 |
| Yoo, JJ | 1 |
| Kim, SG | 1 |
| Kim, YS | 1 |
| Kuo, PH | 1 |
| Sun, HY | 1 |
| Chuang, YC | 1 |
| Wu, PY | 1 |
| Liu, WC | 1 |
| Hung, CC | 1 |
| Leohr, JK | 1 |
| Luffer-Atlas, D | 1 |
| Luo, MJ | 1 |
| DeBrota, DJ | 1 |
| Green, C | 1 |
| Mabry, TE | 1 |
| Suico, JG | 1 |
| Pombo, M | 1 |
| Olalla, J | 1 |
| Del Arco, A | 1 |
| De La Torre, J | 1 |
| Urdiales, D | 1 |
| Aguilar, A | 1 |
| Prada, JL | 1 |
| García-Alegría, J | 1 |
| Ruiz-Mateas, F | 1 |
| Gao, H | 1 |
| Tian, Y | 1 |
| Meng, H | 1 |
| Hou, J | 1 |
| Xu, L | 1 |
| Zhang, L | 1 |
| Shi, D | 1 |
| Lu, R | 1 |
| Feng, X | 1 |
| Wang, X | 1 |
| Chen, Z | 1 |
| Portilla, J | 1 |
| Miralles Alvarez, C | 1 |
| Ribera Pascuet, E | 1 |
| Curran, A | 1 |
| Mikhail, N | 1 |
| Iskander, E | 1 |
| Cope, D | 1 |
| Tungsiripat, M | 1 |
| Kitch, D | 1 |
| Glesby, MJ | 1 |
| Gupta, SK | 1 |
| Mellors, JW | 1 |
| Moran, L | 1 |
| Jones, L | 1 |
| Alston-Smith, B | 1 |
| Rooney, JF | 1 |
| Aberg, JA | 1 |
| Randell, PA | 1 |
| Jackson, AG | 2 |
| Boffito, M | 1 |
| Back, DJ | 1 |
| Tjia, JF | 1 |
| Taylor, J | 1 |
| Mandalia, S | 1 |
| Moyle, GJ | 2 |
| Podzamczer, D | 1 |
| Andrade-Villanueva, J | 1 |
| Clotet, B | 1 |
| Taylor, S | 1 |
| Rockstroh, JK | 1 |
| Reiss, P | 2 |
| Domingo, P | 2 |
| Gellermann, HJ | 1 |
| de Rossi, L | 1 |
| Cairns, V | 1 |
| Soriano, V | 1 |
| Vrouenraets, SM | 1 |
| Wit, FW | 1 |
| Fernandez Garcia, E | 1 |
| Allavena, C | 1 |
| Raffi, F | 1 |
| Jayaweera, DT | 1 |
| Mauss, S | 1 |
| Katlama, C | 1 |
| Fisher, M | 1 |
| Slama, L | 1 |
| Hardy, WD | 1 |
| Dejesus, E | 1 |
| van Eeden, A | 1 |
| Viganò, A | 1 |
| Aldrovandi, GM | 1 |
| Giacomet, V | 1 |
| Merlo, M | 1 |
| Martelli, L | 1 |
| Beretta, S | 1 |
| Luraschi, P | 1 |
| Rombolà, G | 1 |
| Mora, S | 1 |
| Manfredi, R | 1 |
| Llibre, JM | 1 |
| Palacios, R | 1 |
| Santos, J | 1 |
| Pérez-Elías, MJ | 1 |
| Sánchez-de la Rosa, R | 1 |
| Miralles, C | 1 |
| Antela, A | 1 |
| Moreno, S | 1 |
| Ascoli, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects[NCT00109603] | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for adenine and Dyslipidemias
| Article | Year |
|---|---|
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H | 2023 |
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Dou | 2008 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Dis | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug | 2008 |
6 trials available for adenine and Dyslipidemias
| Article | Year |
|---|---|
Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Cholesterol, LDL; Cross-Over Studies; Dyslipidemias; Fem | 2018 |
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dyslipide | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Dr | 2010 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia | 2011 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtr | 2011 |
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2005 |
8 other studies available for adenine and Dyslipidemias
| Article | Year |
|---|---|
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipi | 2020 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba | 2013 |
Associations of apolipoprotein E and low-density lipoprotein receptor-related protein 5 polymorphisms with dyslipidemia and generalized aggressive periodontitis in a Chinese population.
Topics: Adenine; Adolescent; Adult; Aggressive Periodontitis; Apolipoproteins E; Blood Glucose; China; Chole | 2015 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; | 2009 |
Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dyslipidemias; HIV Infections; Huma | 2006 |
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Disease | 2006 |
Effects of hypocholesterolemia and chronic hormonal stimulation on sterol and steroid metabolism in a Leydig cell tumor.
Topics: Adenine; Animals; Cholesterol; Chorionic Gonadotropin; Dyslipidemias; Kinetics; Leydig Cell Tumor; M | 1981 |